肠道菌群对终末期肝病患者营养和代谢的作用

doi:10.3969/j.issn.1672-5069.2017.05.001

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (5): 513-515.doi: 10.3969/j.issn.1672-5069.2017.05.001

• 专家论坛 • 下一篇

肠道菌群对终末期肝病患者营养和代谢的作用

姚佳,原丽莉,段钟平

030031太原市山西大学附属医院消化科（姚佳，原丽莉）；首都医科大学附属北京佑安医院（段钟平）

收稿日期:2017-06-26 出版日期:2017-10-10 发布日期:2017-10-17
通讯作者: 段钟平，E-mail:duan2517@163.com

Contributions of intestinal bacteria to nutrition and metabolism in patients with end-stage liver disease

Yao Jia，Yuan Lili，Duan Zhongping.

Department of Gastroenterology and Hepatology，Affliated Hospital，Shanxi University，Taiyuan 030031，China

Received:2017-06-26 Online:2017-10-10 Published:2017-10-17

摘要/Abstract

关键词: 终末期肝病, 营养不良, 肠道菌群

Key words: End-stage liver disease, Malnutrition, Intestinal bacteria

姚佳,原丽莉,段钟平. 肠道菌群对终末期肝病患者营养和代谢的作用[J]. 实用肝脏病杂志, 2017, 20(5): 513-515.

Yao Jia，Yuan Lili，Duan Zhongping.. Contributions of intestinal bacteria to nutrition and metabolism in patients with end-stage liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 513-515.

[1] Clarke G，Stilling RM，Kennedy PJ，et al. Minireview:Gut microbiota:the neglected endocrine organ. Mol Endocrinol，2014，28:1221-1238.
[2] Flint HJ，Scott KP，Duncan SH，et al. Microbial degradation of complex carbohydrates in the gut. Gut Microbes，2012，3:289-306.
[3] Zhang J，Guo Z，Xue Z，et al. A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles，geography and ethnicities. ISME J，2015，9:1979-1990.
[4] Xu J，Bjursell MK，Himrod J，et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science，2003，299:2074-2076.
[5] Sun P，Wang JQ，Deng LF. Effects of Bacillus subtilis natto on milk production，rumen fermentation and ruminal microbiome of dairy cows. Animal，2013，7:216-222.
[6] Metges CC. Contribution of microbial amino acids to amino acid homeostasis of the host. J Nutr，2000，130:1857S-1864S.
[7] Raj T，Dileep U，Vaz M，et al. Intestinal microbial contribution to metabolic leucine input in adult men. J Nutr，2008，138:2217-2221.
[8] Backhed F，Ding H，Wang T，et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A，2004，101:15718-15723.
[9] Backhed F，Crawford PA. Coordinated regulation of the metabolome and lipidome at the host-microbial interface. Biochim Biophys Acta， 2010，1801:240-245.
[10] Ley RE，Turnbaugh PJ，Klein S，et al. Microbial ecology:human gut microbes associated with obesity. Nature，2006，444:1022-1023.
[11] Rosenbaum M，Knight R，Leibel RL. The gut microbiota in human energy homeostasis and obesity. Trends Endocrinol Metab，2015，26:493-501.
[12] Crawford PA，Crowley JR，Sambandam N，et al. Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci U S A，2009，106:11276-11281.
[13] Kohl KD，Amaya J，Passement CA，et al. Unique and shared responses of the gut microbiota to prolonged fasting:a comparative study across five classes of vertebrate hosts. FEMS Microbiol Ecol，2014，90:883-894.
[14] Maharshi S，Sharma BC，Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality. J Gastroenterol Hepatol，2015，30:1507-1513.
[15] Gomez-Hurtado I，Such J，Sanz Y，et al. Gut microbiota-related complications in cirrhosis. World J Gastroenterol，2014，20:15624-15631.
[16] Chen Y，Guo J，Qian G，et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol，2015，30:1429-1437.
[17] Chen Y，Yang F，Lu H，et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology，2011，54:562-572.
[18] Chen Y，Qin N，Guo J，et al. Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics，2014，15:753.
[19] Wiest R，Lawson M，Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol，2014，60:197-209.
[20] Yao J，Chang L，Yuan L， et al. Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis. Asia Pac J Clin Nutr，2016，25:283-291.
[21] Bures J，Cyrany J，Kohoutova D，et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol，2010，16:2978-2990.
[22] Norman K，Pirlich M，Schulzke JD，et al. Increased intestinal permeability in malnourished patients with liver cirrhosis. Eur J Clin Nutr，2012，66:1116-1119.
[23] Wan X，Bi J，Gao X，et al. Partial enteral nutrition preserves elements of gut barrier function，including innate immunity，intestinal alkaline phosphatase（IAP） level，and intestinal microbiota in mice. Nutrients，2015，7:6294-6312.
[24] Ralls MW，Demehri FR，Feng Y，et al. Enteral nutrient deprivation in patients leads to a loss of intestinal epithelial barrier function. Surgery，2015，157:732-742.
[25] Reiberger T，Ferlitsch A，Payer BA，et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol，2013，58:911-921.
[26] Bajaj JS，Heuman DM，Sanyal AJ，et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One，2013，8:e60042.
[27] Ren ZG，Liu H，Jiang JW，et al. Protective effect of probiotics on intestinal barrier function in malnourished rats after liver transplantation. Hepatobiliary Pancreat Dis Int，2011，10:489-496.
[28]Kao D，Roach B，Park H，et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology，2016，63:339-340.

肠道菌群对终末期肝病患者营养和代谢的作用

Contributions of intestinal bacteria to nutrition and metabolism in patients with end-stage liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[2]	中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 实用肝脏病杂志, 2019, 22(5): 624-635.
[3]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[4]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[5]	王明,张抒,李明,文君,郑振江. 慢性乙型肝炎患者血清与粪便HBV DNA水平对比研究[J]. 实用肝脏病杂志, 2019, 22(2): 176-179.
[6]	郑婷婷, 蒋珊珊, 方钟燎, 陈茂伟. 慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 899-902.
[7]	贾克丽, 韩际奥, 高晓. 血清前白蛋白和MELD评分对失代偿期乙型肝炎肝硬化患者预后的预测价值*[J]. 实用肝脏病杂志, 2018, 21(3): 348-351.
[8]	李磊, 胡辉, 郑晓玮, 江守伟, 沈强. 四种基于MELD的评分系统对慢加急性乙型肝炎肝衰竭患者短期生存的预测价值分析*[J]. 实用肝脏病杂志, 2018, 21(3): 417-420.
[9]	杨蕊旭, 周达, 范建高. 靶向肠道菌群代谢产物防治非酒精性脂肪性肝病*[J]. 实用肝脏病杂志, 2017, 20(6): 643-646.
[10]	谢文瑞, 何兴祥. 粪菌移植与慢性肝脏疾病[J]. 实用肝脏病杂志, 2017, 20(6): 651-653.
[11]	陈鸿杰, 彭劼. 粪便菌群移植与慢性乙型肝炎[J]. 实用肝脏病杂志, 2017, 20(6): 654-657.
[12]	张磊，刘超. 粪菌移植与肝癌[J]. 实用肝脏病杂志, 2017, 20(6): 658-659.
[13]	吴江，范建高. 关注肝病患者肌少症[J]. 实用肝脏病杂志, 2017, 20(5): 516-519.
[14]	宋芳娇，游绍莉，辛绍杰. 终末期肝病营养代谢特点[J]. 实用肝脏病杂志, 2017, 20(5): 520-522.
[15]	王治冲，宋风斌. 失代偿期乙型肝炎肝硬化患者营养状况分析[J]. 实用肝脏病杂志, 2017, 20(2): 236-237.